FDA finalises guidance on its mandatory cosmetics recall power

The Food and Drug Administration has issued final guidance explaining how it intends to use its authority to order the recall of a cosmetic product. The guidance, "Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry," was announced in the Federal Register on 23 October 2026 and sets out the agency's current thinking on "the criteria, process, and expectations, for mandatory recalls of cosmetic products" [s1].

The power itself is relatively new. FDA explains that the guidance addresses "the mandatory cosmetics recall provisions of section 611 of the Federal Food, Drug, and Cosmetic Act, which was added by section 3502 of the Modernization of Cosmetics Regulation Act of 2022" [s1]. That 2022 law, usually shortened to MoCRA, was the most significant expansion of federal cosmetics oversight in decades, and the recall authority is one of its central tools.

What changed with MoCRA

For most of the agency's history, cosmetic recalls in the United States were voluntary: FDA could ask a company to pull a product, publicise a problem, and pressure a manufacturer, but it could not compel a recall the way it long had been able to for some foods and devices. MoCRA changed that for cosmetics by adding section 611 to the Food, Drug, and Cosmetic Act, giving FDA the ability to require a recall under defined conditions rather than relying on a company's cooperation.

The new guidance does not rewrite that statutory authority; it interprets it. Framed as a set of questions and answers, the document "provides answers to common questions that might arise about these mandatory recall provisions and FDA's current thinking regarding their implementation" [s1]. In practice that means explaining to manufacturers when the authority can be triggered, how the process is expected to unfold, and what the agency expects of a company whose product is subject to a mandatory recall.

A final guidance that tracks the draft

The document finalises a draft FDA published earlier. "In the Federal Register of December 18, 2025 (90 FR 59129), FDA announced the availability of the draft guidance," the agency notes [s1]. During the comment period, "FDA received seven comments on the draft guidance, which were broadly supportive of the guidance, and some of which asked for certain clarifications of issues discussed in the guidance" [s1].

After weighing those comments, the agency decided to leave the substance intact: "we are publishing the guidance as drafted with no substantive changes," the notice states, and the document "finalizes the draft guidance dated December 18, 2025" [s1]. A final guidance that mirrors its draft, with only minor clarifications, signals that FDA's approach to cosmetic recalls was not seriously contested by the industry that responded.

What the guidance does and does not do

Like other FDA guidance, the document is not itself a regulation. It is "being issued consistent with FDA's good guidance practices regulation" and "represents the current thinking of FDA on mandatory cosmetics recalls," but "does not establish any rights for any person and is not binding on FDA or the public" [s1]. A company may take an alternative approach so long as it still satisfies the underlying statute and regulations [s1].

The binding force sits in the statute — section 611 of the Food, Drug, and Cosmetic Act — not in the guidance that explains it. What the guidance supplies is predictability: a public statement of how the agency reads its own recall authority, so that manufacturers understand the criteria and process before a problem arises rather than during one. Although the guidance is now final, FDA notes that comments may be submitted "on any guidance at any time," and the document and its background record remain available through the rulemaking docket, FDA-2025-D-2246 [s2].

Why it matters

For consumers, the significance is structural rather than tied to any single product. A mandatory recall authority matters most for the cases that used to be hardest to resolve — a potentially harmful cosmetic whose maker was slow to act voluntarily. By finalising guidance on how it will use section 611, FDA has set out, in public and in writing, the framework it expects to follow when it decides a cosmetic must come off the shelves whether or not the company agrees.

The fixed points are the authority and the interpretation: a mandatory cosmetics recall power created by MoCRA in 2022, and a final FDA guidance, published 23 October 2026, that adopts its December 2025 draft without substantive change.